Supplements vergleichen

Prescription-only and indication-dependent. For fertility preservation / intratesticular-testosterone maintenance on TRT, small studies used ~125-500 IU subcutaneously every other day. For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No dietary-supplement dose exists.

Any time

Verschreibungspflichtiges hCG — rekombinant (Choriogonadotropin alfa) oder aus Urin gewonnen, per Injektion

Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.

Any time

Tamoxifencitrat-Tabletten (zugelassen bei Brustkrebs; off-label bei Männern)

• Hormone-sensitive tumors (e.g. prostate, breast) or other androgen/estrogen-dependent conditions
• Known hypersensitivity to hCG
• Use without medical supervision

• Exogenous testosterone / anabolic steroids
• FSH / hMG (menotropins)
• Aromatase inhibitors (e.g. anastrozole)

• History of venous thromboembolism (deep-vein thrombosis or pulmonary embolism) or stroke — tamoxifen raises clot risk
• Concurrent warfarin / anticoagulant therapy in the prevention setting (per label)
• Pregnancy and breastfeeding (can harm the fetus)

• Warfarin / anticoagulants
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, bupropion)
• Aromatase inhibitors / other SERMs / exogenous estrogens